Hedley Mary Lynne, an insider at Eli Lilly and Co (LLY), purchased 2,241 shares of the company on November 16, 2025, at a price of $1,021.70 per share, amounting to a total investment of $2.29 million. Following this transaction, Mary Lynne holds 2,241 shares of Eli Lilly.
Eli Lilly operates in the pharmaceuticals sector, focusing on the discovery, development, manufacture, and sale of pharmaceutical products. The company, headquartered in Indianapolis, Indiana, employs approximately 47,000 individuals. Its diverse product portfolio includes cardiometabolic health products such as Humalog and Trulicity, oncology products like Verzenio, and immunology treatments including Taltz.
This insider purchase may be interpreted as a sign of confidence in the company's future, as executives typically possess insights into their firm's operations. However, it is essential for investors to consider such transactions within a broader context, as many factors can influence insider trading decisions.
Insider transactions must be reported to the SEC, providing transparency into executive sentiment regarding company stock. While this single purchase represents one data point for investors, examining trends across multiple insiders and time periods can yield more comprehensive insights. Eli Lilly's market cap stands at $965.9 billion, with a P/E ratio of 52.46 and an EPS of 20.45. The company is expected to report earnings on April 28, 2026, with an estimated EPS of $7.16 and revenue of $17.1 billion.